NasdaqGM - Nasdaq Real Time Price USD
Keros Therapeutics, Inc. (KROS)
13.47
-0.27
(-1.97%)
At close: May 13 at 4:00:02 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 237,367 | 5 |
| Sales | 40,000 | 1 |
| Net Shares Purchased (Sold) | 197,367 | 6 |
| Total Insider Shares Held | 921.97k | -- |
| % Net Shares Purchased (Sold) | 27.20% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| SEEHRA JASBIR Chief Executive Officer | Conversion of Exercise of derivative security at price 0.30 per share. | Direct | 14,810 | Apr 4, 2025 |
| REGNANTE KEITH C Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 18, 2025 |
| ROVALDI CHRISTOPHER Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 18, 2025 |
| CHYUNG YUNG H. M.D. Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 18, 2025 |
| GORDON CARL L Director | Sale at price 44.01 per share. | Indirect | 11,002,500 | Aug 13, 2024 |
| ORBIMED ADVISORS, L.L.C. Unknown | Sale at price 44.01 per share. | Indirect | 11,002,500 | Aug 13, 2024 |
| REGNANTE KEITH C Chief Financial Officer | Sale at price 45.29 per share. | Direct | 1,811,600 | Jan 4, 2024 |
| REGNANTE KEITH C Chief Financial Officer | Conversion of Exercise of derivative security at price 16.00 per share. | Direct | 640,000 | Jan 4, 2024 |
| REGNANTE KEITH C Chief Financial Officer | Sale at price 31.94 per share. | Direct | 1,277,600 | Nov 3, 2023 |
| REGNANTE KEITH C Chief Financial Officer | Conversion of Exercise of derivative security at price 16.00 per share. | Direct | 640,000 | Nov 3, 2023 |
| REGNANTE KEITH C Chief Financial Officer | Sale at price 45.03 - 48.65 per share. | Direct | 1,864,239 | Jun 9, 2023 |
| REGNANTE KEITH C Chief Financial Officer | Conversion of Exercise of derivative security at price 16.00 per share. | Direct | 640,000 | Jun 9, 2023 |
Related Tickers
ITOS iTeos Therapeutics, Inc.
7.85
+13.44%
RPTX Repare Therapeutics Inc.
1.4300
+5.15%
ANTX AN2 Therapeutics, Inc.
1.1800
-0.84%
ASMB Assembly Biosciences, Inc.
12.34
-0.08%
CYTK Cytokinetics, Incorporated
30.61
-4.73%
HLVX HilleVax, Inc.
1.9200
+1.59%
CRGX CARGO Therapeutics, Inc.
3.9700
-2.46%
VTYX Ventyx Biosciences, Inc.
1.2000
-0.83%
KZR Kezar Life Sciences, Inc.
4.2000
-0.71%
EPIX ESSA Pharma Inc.
1.6700
-0.60%